CoChat

Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP

Open access
Wiseman, Frances K, Pulford, Laura J, Barkus, Chris, Liao, Fan, Portelius, Erik, Webb, Robin, Chávez-Gutiérrez, Lucia, Cleverley, Karen, Noy, Sue, Sheppard, Olivia, Collins, Toby, Powell, Caroline, Sarell, Claire J, Rickman, Matthew, Choong, Xun, Tosh, Justin L, Siganporia, Carlos, Whittaker, Heather T, Stewart, Floy, Szaruga, Maria, London Down syndrome consortium, Murphy, Michael P, Blennow, Kaj, de Strooper, Bart, Zetterberg, Henrik, Bannerman, David, Holtzman, David M, Tybulewicz, Victor L J, Fisher, Elizabeth M C, The LonDownS Consortium, Strydom, Andre, Fisher, Elizabeth, Nizetic, Dean, Hardy, John, Tybulewicz, Victor, Karmiloff-Smith, Annette · 2018 · Brain

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.

Abstract

Down syndrome, caused by trisomy of chromosome 21, is the single most common risk factor for early-onset Alzheimer's disease. Worldwide approximately 6 million people have Down syndrome, and all these individuals will develop the hallmark amyloid plaques and neurofibrillary tangles of Alzheimer's disease by the age of 40 and the vast majority will go on to develop dementia. Triplication of APP, a gene on chromosome 21, is sufficient to cause early-onset Alzheimer's disease in the absence of Down syndrome. However, whether triplication of other chromosome 21 genes influences disease pathogenesis in the context of Down syndrome is unclear. Here we show, in a mouse model, that triplication of chromosome 21 genes other than APP increases amyloid-β aggregation, deposition of amyloid-β plaques and worsens associated cognitive deficits. This indicates that triplication of chromosome 21 genes other than APP is likely to have an important role to play in Alzheimer's disease pathogenesis in individuals who have Down syndrome. We go on to show that the effect of trisomy of chromosome 21 on amyloid-β aggregation correlates with an unexpected shift in soluble amyloid-β 40/42 ratio. This alteration in amyloid-β isoform ratio occurs independently of a change in the carboxypeptidase activity of the γ-secretase complex, which cleaves the peptide from APP, or the rate of extracellular clearance of amyloid-β. These new mechanistic insights into the role of triplication of genes on chromosome 21, other than APP, in the development of Alzheimer's disease in individuals who have Down syndrome may have implications for the treatment of this common cause of neurodegeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awy159

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trisomy of chromosome 21 promotes the intracellular and extracellular deposition of amyloid-β. (A and B) Intracellular amyloid-β deposition (82E1) was increased by trisomy in hippocampal CA3 pyramidal neurons in 4.5–6.5-month-old mice [ANOVA trisomy-tgAPP interaction F(1,31) = 5.125, P = 0.031] [Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.012; wild-type (WT) (black circles) n = 10, trisomic (blue squares) n = 10, tgAPP (red triangles) n = 10, trisomic;tgAPP (purple inverted triangles) n = 10]. (C) A trend for increased hippocampal Tris-soluble multimeric amyloid-β (82E1-82E1 ELISA) normalized to the sum of amyloid-β38, amyloid-β40 and amyloid-β42 in trisomic;tgAPP was observed [trisomy F(1,24) = 3.928, P = 0.059; tgAPP n = 8, trisomic;tgAPP n = 11)]. (D–I) Amyloid-β deposition (6F/3D) in the hippocampus was quantified at (D–F) 6 and (G–I) 16 months of age. Trisomy increases (E and H) the number of plaques [tgAPP–trisomy interaction F(1,77) = 6.744, P = 0.011, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.008, 16 months P = 0.003] and (F and I) the area covered by amyloid-β [tgAPP–trisomy interaction F(1,85) = 4.005, P = 0.049, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.097, 16 months P = 0.037] (6 months wild-type n = 8, trisomic = 8, tgAPP n = 15, trisomic;tgAPP n = 13; 16 months wild-type n = 16, trisomic = 9, tgAPP n = 13, trisomic;tgAPP n = 11). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were studied and sex was included as a factor in the ANOVA. Scale bar in A = 50 µm; D and G = 500 µm. Aβ = amyloid-β.
Figure 1 Trisomy of chromosome 21 promotes the intracellular and extracellular deposition of amyloid-β. (A and B) Intracellular amyloid-β deposition (82E1) was increased by trisomy in hippocampal CA3 pyramidal neurons in 4.5–6.5-month-old mice [ANOVA trisomy-tgAPP interaction F(1,31) = 5.125, P = 0.031] [Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.012; wild-type (WT) (black circles) n = 10, trisomic (blue squares) n = 10, tgAPP (red triangles) n = 10, trisomic;tgAPP (purple inverted triangles) n = 10]. (C) A trend for increased hippocampal Tris-soluble multimeric amyloid-β (82E1-82E1 ELISA) normalized to the sum of amyloid-β38, amyloid-β40 and amyloid-β42 in trisomic;tgAPP was observed [trisomy F(1,24) = 3.928, P = 0.059; tgAPP n = 8, trisomic;tgAPP n = 11)]. (D–I) Amyloid-β deposition (6F/3D) in the hippocampus was quantified at (D–F) 6 and (G–I) 16 months of age. Trisomy increases (E and H) the number of plaques [tgAPP–trisomy interaction F(1,77) = 6.744, P = 0.011, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.008, 16 months P = 0.003] and (F and I) the area covered by amyloid-β [tgAPP–trisomy interaction F(1,85) = 4.005, P = 0.049, Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP 6 months P = 0.097, 16 months P = 0.037] (6 months wild-type n = 8, trisomic = 8, tgAPP n = 15, trisomic;tgAPP n = 13; 16 months wild-type n = 16, trisomic = 9, tgAPP n = 13, trisomic;tgAPP n = 11). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were studied and sex was included as a factor in the ANOVA. Scale bar in A = 50 µm; D and G = 500 µm. Aβ = amyloid-β.CC BY · PubMed Central
Figure 2 Trisomy of chromosome 21 promotes the aggregation of amyloid-β. (A–F) Cortical proteins from 16-month-old mice were fractionated and 5 M guanidine hydrochloride soluble amyloid-β quantified by (A–E) Meso Scale Discovery Assay or (F) mass spectrometry. (A and B) No effect of trisomy on amyloid-β38 [tgAPP-trisomy interaction F(1,28) = 0.385, P = 0.540] or amyloid-β40 [tgAPP-trisomy interaction F(1,28) = 0.962, P = 0.355] was observed, (C) but significantly more amyloid-β42 was detected in trisomic;tgAPP mice [tgAPP-trisomy interaction F(1,28) = 5.573, P = 0.025] (Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.005, wild-type n = 6, trisomic = 6, tgAPP n = 13, trisomic;tgAPP n = 11). (D and E) No change in the amyloid-β38/42 ratio [trisomy F(1,19) = 0.072, P = 0.792] or amyloid-β40/42 ratio [trisomy F(1,19) = 0.047, P = 0.831] was observed. (F) The relative abundance of different forms of amyloid-β peptides was not altered by trisomy of chromosome 21 (tgAPP n = 12, trisomic;tgAPP n = 10). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a factor in the ANOVA. Aβ = amyloid-β; WT = wild-type.
Figure 2 Trisomy of chromosome 21 promotes the aggregation of amyloid-β. (A–F) Cortical proteins from 16-month-old mice were fractionated and 5 M guanidine hydrochloride soluble amyloid-β quantified by (A–E) Meso Scale Discovery Assay or (F) mass spectrometry. (A and B) No effect of trisomy on amyloid-β38 [tgAPP-trisomy interaction F(1,28) = 0.385, P = 0.540] or amyloid-β40 [tgAPP-trisomy interaction F(1,28) = 0.962, P = 0.355] was observed, (C) but significantly more amyloid-β42 was detected in trisomic;tgAPP mice [tgAPP-trisomy interaction F(1,28) = 5.573, P = 0.025] (Bonferroni pairwise comparisons trisomic;tgAPP with tgAPP P = 0.005, wild-type n = 6, trisomic = 6, tgAPP n = 13, trisomic;tgAPP n = 11). (D and E) No change in the amyloid-β38/42 ratio [trisomy F(1,19) = 0.072, P = 0.792] or amyloid-β40/42 ratio [trisomy F(1,19) = 0.047, P = 0.831] was observed. (F) The relative abundance of different forms of amyloid-β peptides was not altered by trisomy of chromosome 21 (tgAPP n = 12, trisomic;tgAPP n = 10). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a factor in the ANOVA. Aβ = amyloid-β; WT = wild-type.CC BY · PubMed Central
Figure 3 Trisomy of chromosome 21 exacerbates APP/amyloid-β-associated cognitive deficits. (A and B) Exposure to a novel open field was used as a test of activity and habituation (6 months, wild-type n = 28, trisomic n = 28, TgAPP n = 20, trisomic;tgAPP n = 18). (A) Overall activity: ANOVA of distance travelled revealed a main effect of tgAPP [F(1,78) = 26.250, P < 0.001], trisomy [F(1,78) = 9.246, P = 0.003], and a tgAPP-trisomy interaction [F(1,78) = 7.818, P = 0.007] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P = 0.008). (B) The total distance moved declined with exposure time (1-min time bins) ANOVA: main effect of time bin [F(29,2262) = 12.399 P < 0.001]; an interaction of time bin × trisomy [ANOVA F(29,2262) = 1.789 P = 0.006], time bin × tgAPP [F(29,2262) = 1.560 P = 0.029] and time bin × trisomy;tgAPP [F(29,2262) = 1.983, P < 0.001] was observed by ANOVA. (C and D) A Y-maze spatial novelty preference task (1-min delay) was used as a test of activity and memory. (Cohort B 2–3 months and Cohort A 6–7 months, the effect of genotype was similar in both cohorts so data were combined for analysis, wild-type n = 45, trisomic n = 43, TgAPP n = 36, trisomic;tgAPP n = 26). (C) ANOVA of the number of arm entries (test phase), revealed a main effect of trisomy [F(1,89) = 50.360, P < 0.001], tgAPP [F(1,89) = 47.001, P < 0.001], and a tgAPP–trisomy interaction [F(1,89) = 31.720, P < 0.001] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P < 0.001). (D) A preference ratio of 0.5 indicates chance performance (black dotted line). ANOVA of novelty preference revealed a main effect of trisomy [F(1,89) = 10.144 P = 0.002], tgAPP [F(1,89) = 9.312 P = 0.003] and a tgAPP–trisomy interaction [F(1,89) = 5.736, P = 0.019] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001 and trisomic P = 0.010). Performance of tgAPP–trisomic mice was above chance (one-sample t-test t = 3.287 P < 0.001). (E) A discrete-trial, longitudinal spontaneous alternation task in a T-maze was used as a test of memory, 50% alternation represents chance performance (black dotted line) (2–3 months wild-type n = 29, trisomic n = 30, TgAPP n = 21, trisomic;tgAPP n = 17, 6–7 months wild-type n = 28, trisomic n = 29, TgAPP n = 20, trisomic;tgAPP n = 17, 15–16 months wld-type n = 27, trisomic n = 26, TgAPP n = 27, trisomic;tgAPP n = 11). ANOVA of alternation showed a main effect of trisomy [F(1,67) = 7.084 P = 0.010], and an interaction of tgAPP–trisomy [F(1,67) = 4.706, P = 0.034] (Bonferroni pairwise comparison trisomic;tgAPP with wild-type P = 0.032). Performance of tgAPP-trisomic mice was above chance (one-sample t-test, 2–3 months t = 5.884 P < 0.001, 6–7 months t = 5.378 P < 0.001, 15–16 months t = 6.495 P < 0.001). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.
Figure 3 Trisomy of chromosome 21 exacerbates APP/amyloid-β-associated cognitive deficits. (A and B) Exposure to a novel open field was used as a test of activity and habituation (6 months, wild-type n = 28, trisomic n = 28, TgAPP n = 20, trisomic;tgAPP n = 18). (A) Overall activity: ANOVA of distance travelled revealed a main effect of tgAPP [F(1,78) = 26.250, P < 0.001], trisomy [F(1,78) = 9.246, P = 0.003], and a tgAPP-trisomy interaction [F(1,78) = 7.818, P = 0.007] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P = 0.008). (B) The total distance moved declined with exposure time (1-min time bins) ANOVA: main effect of time bin [F(29,2262) = 12.399 P < 0.001]; an interaction of time bin × trisomy [ANOVA F(29,2262) = 1.789 P = 0.006], time bin × tgAPP [F(29,2262) = 1.560 P = 0.029] and time bin × trisomy;tgAPP [F(29,2262) = 1.983, P < 0.001] was observed by ANOVA. (C and D) A Y-maze spatial novelty preference task (1-min delay) was used as a test of activity and memory. (Cohort B 2–3 months and Cohort A 6–7 months, the effect of genotype was similar in both cohorts so data were combined for analysis, wild-type n = 45, trisomic n = 43, TgAPP n = 36, trisomic;tgAPP n = 26). (C) ANOVA of the number of arm entries (test phase), revealed a main effect of trisomy [F(1,89) = 50.360, P < 0.001], tgAPP [F(1,89) = 47.001, P < 0.001], and a tgAPP–trisomy interaction [F(1,89) = 31.720, P < 0.001] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001, trisomic P < 0.001, and tgAPP P < 0.001). (D) A preference ratio of 0.5 indicates chance performance (black dotted line). ANOVA of novelty preference revealed a main effect of trisomy [F(1,89) = 10.144 P = 0.002], tgAPP [F(1,89) = 9.312 P = 0.003] and a tgAPP–trisomy interaction [F(1,89) = 5.736, P = 0.019] (Bonferroni pairwise comparisons trisomic;tgAPP with wild-type P < 0.001 and trisomic P = 0.010). Performance of tgAPP–trisomic mice was above chance (one-sample t-test t = 3.287 P < 0.001). (E) A discrete-trial, longitudinal spontaneous alternation task in a T-maze was used as a test of memory, 50% alternation represents chance performance (black dotted line) (2–3 months wild-type n = 29, trisomic n = 30, TgAPP n = 21, trisomic;tgAPP n = 17, 6–7 months wild-type n = 28, trisomic n = 29, TgAPP n = 20, trisomic;tgAPP n = 17, 15–16 months wld-type n = 27, trisomic n = 26, TgAPP n = 27, trisomic;tgAPP n = 11). ANOVA of alternation showed a main effect of trisomy [F(1,67) = 7.084 P = 0.010], and an interaction of tgAPP–trisomy [F(1,67) = 4.706, P = 0.034] (Bonferroni pairwise comparison trisomic;tgAPP with wild-type P = 0.032). Performance of tgAPP-trisomic mice was above chance (one-sample t-test, 2–3 months t = 5.884 P < 0.001, 6–7 months t = 5.378 P < 0.001, 15–16 months t = 6.495 P < 0.001). Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and female mice were used and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.CC BY · PubMed Central
Figure 4 Trisomy of chromosome 21 genes other than APP does not increase APP abundance nor alter β-CTF/α-CTF ratio. (A, B and D) Full-length APP (FL-APP), APP β-CTF and APP α-CTF were measured in cortex (wild-type n = 17, trisomic n = 16, tgAPP n = 24, trisomic;tgAPP n = 19) and hippocampus (wild-type n = 11, trisomic n = 12, tgAPP n = 24, trisomic;tgAPP n = 17) at 3 months of age. (A) Full-length APP was higher in tgAPP and trisomic;tgAPP compared with wild-type or trisomic mice [cortex F(1,68) = 87.667, P < 0.001, hippocampus F(1,56) = 94.301, P < 0.001]. Trisomy did not alter full-length APP [trisomy–tgAPP interaction, cortex F(1,68) = 0.483, P = 0.489, hippocampus F(1,56) = 2.457, P = 0.123]. (B and C) In male mice, APP-CTF/full-length APP ratio was altered (cortex tgAPP n = 17, trisomic;tgAPP n = 11, hippocampus tgAPP n = 14, trisomic;tgAPP n = 8) β-CTF/full-length APP (t-test cortex P = 0.005, hippocampus P = 0.0217) and α-CTF/full-length APP (t-test cortex P = 0.005 hippocampus P < 0.001). (D) Trisomy did not alter the β-CTF/α-CTF ratio in the cortex [trisomy F(1,37) = 0.065, P = 0.799] or hippocampus [trisomy F(1,37) = 1.082, P = 0.305]. (B) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. WT = wild-type.
Figure 4 Trisomy of chromosome 21 genes other than APP does not increase APP abundance nor alter β-CTF/α-CTF ratio. (A, B and D) Full-length APP (FL-APP), APP β-CTF and APP α-CTF were measured in cortex (wild-type n = 17, trisomic n = 16, tgAPP n = 24, trisomic;tgAPP n = 19) and hippocampus (wild-type n = 11, trisomic n = 12, tgAPP n = 24, trisomic;tgAPP n = 17) at 3 months of age. (A) Full-length APP was higher in tgAPP and trisomic;tgAPP compared with wild-type or trisomic mice [cortex F(1,68) = 87.667, P < 0.001, hippocampus F(1,56) = 94.301, P < 0.001]. Trisomy did not alter full-length APP [trisomy–tgAPP interaction, cortex F(1,68) = 0.483, P = 0.489, hippocampus F(1,56) = 2.457, P = 0.123]. (B and C) In male mice, APP-CTF/full-length APP ratio was altered (cortex tgAPP n = 17, trisomic;tgAPP n = 11, hippocampus tgAPP n = 14, trisomic;tgAPP n = 8) β-CTF/full-length APP (t-test cortex P = 0.005, hippocampus P = 0.0217) and α-CTF/full-length APP (t-test cortex P = 0.005 hippocampus P < 0.001). (D) Trisomy did not alter the β-CTF/α-CTF ratio in the cortex [trisomy F(1,37) = 0.065, P = 0.799] or hippocampus [trisomy F(1,37) = 1.082, P = 0.305]. (B) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. WT = wild-type.CC BY · PubMed Central
Figure 5 Trisomy of chromosome 21 genes other than APP does not alter α-/β-secretase activity. Trisomy did not alter (A) soluble β-APP abundance [trisomy F(1,24) = 0.790, P = 0.383, trisomy-tgAPP interaction F(1,24) = 0.773, P = 0.388, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14], (B and C) cortical BACE1 abundance [trisomy F(1,24) = 0.002, P = 0.963; trisomy–tgAPP interaction F(1,24) = 0.071, P = 0.792, wild-type n = 6, trisomic n = 6, TgAPP n = 9, trisomic;tgAPP n = 7], (D) BACE1 β-secretase activity [trisomy F(1,13) = 0.006, P = 0.941; trisomy–tgAPP interaction F(1,13) = 0.001 P = 0.971, wild-type n = 6, trisomic n = 6, TgAPP n = 4, trisomic;tgAPP n = 5], or (E) soluble α-APP abundance [trisomy F(1,27) = 0.041, P = 0.841; trisomy–tgAPP interaction F(1,27) = 0.002, P = 0.969, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14]. (C) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM. Both sexes were analysed and sex was included as a factor in the ANOVA. Aβ = amyloid-β.
Figure 5 Trisomy of chromosome 21 genes other than APP does not alter α-/β-secretase activity. Trisomy did not alter (A) soluble β-APP abundance [trisomy F(1,24) = 0.790, P = 0.383, trisomy-tgAPP interaction F(1,24) = 0.773, P = 0.388, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14], (B and C) cortical BACE1 abundance [trisomy F(1,24) = 0.002, P = 0.963; trisomy–tgAPP interaction F(1,24) = 0.071, P = 0.792, wild-type n = 6, trisomic n = 6, TgAPP n = 9, trisomic;tgAPP n = 7], (D) BACE1 β-secretase activity [trisomy F(1,13) = 0.006, P = 0.941; trisomy–tgAPP interaction F(1,13) = 0.001 P = 0.971, wild-type n = 6, trisomic n = 6, TgAPP n = 4, trisomic;tgAPP n = 5], or (E) soluble α-APP abundance [trisomy F(1,27) = 0.041, P = 0.841; trisomy–tgAPP interaction F(1,27) = 0.002, P = 0.969, wild-type n = 4, trisomic n = 4, TgAPP n = 13, trisomic;tgAPP n = 14]. (C) Cropped western blot, four lanes of an eight-lane gel. Data are represented as mean ± SEM. Both sexes were analysed and sex was included as a factor in the ANOVA. Aβ = amyloid-β.CC BY · PubMed Central
Figure 6 Trisomy of chromosome 21 does not alter the half-life of extracellular amyloid-β. (A and B) The in vivo half-life of amyloid-β40, measured by microdialysis of hippocampal interstitial fluid (ISF), was not altered by trisomy of chromosome 21. Compound E injected at 6 h to halt further amyloid-β generation (t-test P = 0.258, tgAPP n = 8, trisomic;tgAPP n = 6 females only). Data are represented as mean ± SEM. Aβ = amyloid-β.
Figure 6 Trisomy of chromosome 21 does not alter the half-life of extracellular amyloid-β. (A and B) The in vivo half-life of amyloid-β40, measured by microdialysis of hippocampal interstitial fluid (ISF), was not altered by trisomy of chromosome 21. Compound E injected at 6 h to halt further amyloid-β generation (t-test P = 0.258, tgAPP n = 8, trisomic;tgAPP n = 6 females only). Data are represented as mean ± SEM. Aβ = amyloid-β.CC BY · PubMed Central
Figure 7 Trisomy of chromosome 21 modulates amyloid-β ratios in vivo independently of modulation of γ-secretase activity. (A–C) Tris-soluble amyloid-β38, amyloid-β40 and amyloid-β42 were measured by Meso Scale Discovery 6E10 Aβ Triplex assay in 2-month-old hippocampus (wild-type n = 24, trisomic n = 22, TgAPP n = 25 and trisomic;tgAPP n = 27). (A) Trisomy decreased amyloid-β38 [trisomy F(1,4) = 15.403, P = 0.017] and amyloid-β40 [trisomy F(1,11) = 6.359, P = 0.028], but amyloid-β42 was not changed [trisomy F(1,11) = 2.978, P = 0.112], (B) resulting in an alteration in the amyloid-β38/42 ratio [trisomy F(1,4) = 14.553, P = 0.019] and (C) the amyloid-β40/42 ratio [trisomy F(1,10) = 95.694, P < 0.001]. (D) Hippocampal amyloid-β40/42 ratio negatively correlates with the relative abundance of aggregated amyloid-β (multimeric 82E1-82E1 amyloid-β ELISA) (linear correlation, R2 = 0.5485, P = 0.0003, tgAPP n = 8, trisomic;tgAPP n = 11). Trisomy did not alter the carboxypeptidase activity of the γ-secretase complex, as measured by (E and G) amyloid-β38/42 and (F and H) amyloid-β40/42 ratios produced in vitro by the complex isolated from cortex from (E and F) the Tc1 trisomic mouse [trisomy amyloid-β38/42 F(1,11) = 4.88, P = 0.499; amyloid-β42/40 F(1,11) = 0.799, P = 0.395, wild-type = 9, trisomic = 9] and (G and H) people with Down syndrome and Alzheimer’s disease (AD-DS) (n = 6) compared with age- and sex-matched individuals who did not have Down syndrome or dementia (control n = 6) [trisomy amyloid-β38/42 F(1,5) = 0.102, P = 0.763; amyloid-β42/40 F(1,5) = 0.187, P = 0.684]. (A–F) Data are represented as mean ± SEM, (G and H) individual cases plotted, horizontal line indicates mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and females were studied and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.
Figure 7 Trisomy of chromosome 21 modulates amyloid-β ratios in vivo independently of modulation of γ-secretase activity. (A–C) Tris-soluble amyloid-β38, amyloid-β40 and amyloid-β42 were measured by Meso Scale Discovery 6E10 Aβ Triplex assay in 2-month-old hippocampus (wild-type n = 24, trisomic n = 22, TgAPP n = 25 and trisomic;tgAPP n = 27). (A) Trisomy decreased amyloid-β38 [trisomy F(1,4) = 15.403, P = 0.017] and amyloid-β40 [trisomy F(1,11) = 6.359, P = 0.028], but amyloid-β42 was not changed [trisomy F(1,11) = 2.978, P = 0.112], (B) resulting in an alteration in the amyloid-β38/42 ratio [trisomy F(1,4) = 14.553, P = 0.019] and (C) the amyloid-β40/42 ratio [trisomy F(1,10) = 95.694, P < 0.001]. (D) Hippocampal amyloid-β40/42 ratio negatively correlates with the relative abundance of aggregated amyloid-β (multimeric 82E1-82E1 amyloid-β ELISA) (linear correlation, R2 = 0.5485, P = 0.0003, tgAPP n = 8, trisomic;tgAPP n = 11). Trisomy did not alter the carboxypeptidase activity of the γ-secretase complex, as measured by (E and G) amyloid-β38/42 and (F and H) amyloid-β40/42 ratios produced in vitro by the complex isolated from cortex from (E and F) the Tc1 trisomic mouse [trisomy amyloid-β38/42 F(1,11) = 4.88, P = 0.499; amyloid-β42/40 F(1,11) = 0.799, P = 0.395, wild-type = 9, trisomic = 9] and (G and H) people with Down syndrome and Alzheimer’s disease (AD-DS) (n = 6) compared with age- and sex-matched individuals who did not have Down syndrome or dementia (control n = 6) [trisomy amyloid-β38/42 F(1,5) = 0.102, P = 0.763; amyloid-β42/40 F(1,5) = 0.187, P = 0.684]. (A–F) Data are represented as mean ± SEM, (G and H) individual cases plotted, horizontal line indicates mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001. Both male and females were studied and sex was included as a variable in the ANOVA. Aβ = amyloid-β; WT = wild-type.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 133

Metadata

Authors
Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., Collins, T., Powell, C., Sarell, C. J., Rickman, M., Choong, X., Tosh, J. L., Siganporia, C., Whittaker, H. T., Stewart, F., Szaruga, M., London Down syndrome consortium, Murphy, M. P., Blennow, K., de Strooper, B., Zetterberg, H., Bannerman, D., Holtzman, D. M., Tybulewicz, V. L. J., Fisher, E. M. C., The LonDownS Consortium, Strydom, A., Fisher, E., Nizetic, D., Hardy, J., Tybulewicz, V., & Karmiloff-Smith, A.
Affiliations
  • King's College London (GB)
  • UCL Queen Square Institute of Neurology (GB)
  • University of Oxford (GB)
  • Washington University in St. Louis (US)
  • University of Gothenburg (SE)
  • University of Kentucky (US)
  • VIB-KU Leuven Center for Brain and Disease Research, VIB-Leuven 3000, Center for Human Genetics, Universitaire Ziekenhuizen and LIND, KU Leuven, Leuven, Belgium
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 3BG UK
  • MRC Prion Unit (GB)
  • UK Dementia Research Institute (GB)
  • The LonDownS Consortium, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London, SE5 8AF, UK
Venue
Brain
Published
2018-06-26
Volume
141
Issue
8
Pages
2457-2474
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2810011474
Cited by
133
References
68
Citations by year
2026: 9 · 2025: 19 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 4
FWCI
10.58
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, cc-by)
  • Lirias (submittedVersion, other-oa)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • Wellcome Trust Strategic Award (098330/Z/12/Z)
  • London Down Syndrome (LonDownS) Consortium
  • Wellcome Trust Joint Senior Investigators Award
  • Medical Research Council (U117527252, G0601056, FC001194)
  • Alzheimer’s Research UK
  • Alzheimer’s Society
  • Epilepsy Research UK
  • Torsten Söderberg Foundation at the Royal Swedish Academy of Sciences
  • Francis Crick Institute
  • Cancer Research UK (FC001194)
  • Wellcome Trust (FC001194)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Down syndrome, amyloid-beta deposition, amyloid plaques, Alzheimer's disease, amyloid-beta aggregation, cognitive impairment, gamma-secretase, APP, mouse model
MeSH terms
Alzheimer Disease, Animals, Brain, Disease Models, Animal, Down Syndrome, Female, Humans, Male, Mice, Inbred C57BL, Trisomy, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.